| Bid | 2.7 |
| Market Cap | 363.35M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.05 |
| PE Ratio (ttm) | -57.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.86 |
| Volume | 183,123 |
| Avg. Volume (20D) | 713,144 |
| Open | 3.04 |
| Previous Close | 3.00 |
| Day's Range | 2.88 - 3.08 |
| 52-Week Range | 2.17 - 4.57 |
| Beta | undefined |
About ORGO
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy ...
Analyst Forecast
According to 2 analyst ratings, the average rating for ORGO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 73.01% from the latest price.
Next Earnings Release
Analysts project revenue of $104.60M, reflecting a 4.97% YoY growth and earnings per share of -0.01, making a -200.00% decrease YoY.
2 months ago · seekingalpha.com
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call TranscriptOrganogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francis...
